Spyre Therapeutics Dividend
Dividend criteria checks 0/6
Spyre Therapeutics does not have a record of paying a dividend.
Key information
n/a
Dividend yield
n/a
Payout ratio
Industry average yield | 2.0% |
Next dividend pay date | n/a |
Ex dividend date | n/a |
Dividend per share | n/a |
Earnings per share | -US$3.66 |
Dividend yield forecast in 3Y | n/a |
Recent dividend updates
No updates
Recent updates
Aeglea BioTherapeutics (NASDAQ:AGLE) Will Have To Spend Its Cash Wisely
Feb 24We're A Little Worried About Aeglea BioTherapeutics' (NASDAQ:AGLE) Cash Burn Rate
Oct 28Aeglea stock jumps ~58% after hours on European nod for enzyme pegzilarginase
Aug 18Aeglea BioTherapeutics GAAP EPS of -$0.27 beats by $0.04, revenue of $0.63M misses by $0.08M
Aug 04Can Aeglea BioTherapeutics (NASDAQ:AGLE) Afford To Invest In Growth?
Jun 09Aeglea Presents Itself As Buy Opportunity After Latest Data Causes Stock To Trade Lower
Dec 07Industry Analysts Just Made A Stunning Upgrade To Their Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Revenue Forecasts
Aug 10Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Just Reported Second-Quarter Earnings And Analysts Are Lifting Their Estimates
Aug 08Aeglea BioTherapeutics EPS misses by $0.14
May 10Aeglea completes patient randomization in late-stage pegzilarginase trial
May 03What You Need To Know About Aeglea BioTherapeutics, Inc.'s (NASDAQ:AGLE) Investor Composition
Mar 17We Think Aeglea BioTherapeutics (NASDAQ:AGLE) Needs To Drive Business Growth Carefully
Feb 10Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if SYRE's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if SYRE's dividend payments have been increasing.
Dividend Yield vs Market
Spyre Therapeutics Dividend Yield vs Market |
---|
Segment | Dividend Yield |
---|---|
Company (SYRE) | n/a |
Market Bottom 25% (US) | 1.4% |
Market Top 25% (US) | 4.4% |
Industry Average (Biotechs) | 2.0% |
Analyst forecast in 3 Years (SYRE) | n/a |
Notable Dividend: Unable to evaluate SYRE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate SYRE's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate SYRE's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as SYRE has not reported any payouts.